Study in neuroblastoma demonstrated that anlotinib could reprogram an immunosuppressive TME into an immunostimulatory environment, curbing tumor growth and preventing systemic immunosuppression, while in lung cancer, it was shown to inhibit M2 polarization of TAMs through the AKT/mTORC1 and Pparδ pathways (61, 62). Here, PPARD is linked to lung carcinoma.